Capital Structure
Idea Slides
Chart
GBT's 50MA has served as key support throughout 2019 and the recent dip appears to allow investors another advantageous buying point.
Introduction
Global Blood Therapeutics (GBT) remains a top conviction pick in 2Q 2019, as the company preps for additional HOPE data & NDA submission in 2H 2019. In this update we will discuss the following:
- Voxelotor is, still, likely a drug that will not only reduce the hemolytic anemia associated with sickle cell disease, but also vasoocclusive crises, making it a more attractive option for patients
- Newly-licensed